Due to a high workload volume and ensuring submissions are reviewed in a timely manner, CADTH is deferring the effective ... Read More
Events
30
Mar2016
30
Mar2016
Minimum Period of 120 Calendar Days for Advance Notification of Anticipated Submissions and Resubmissions for CADTH’s CDR and pCODR Programs
/ CADTH, CDEC, CDR, pCODR, What's New
Recommendation Framework for CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) Programs
In collaboration with the participating jurisdictions ... Read More
24
Mar2016
The PMPRB to Implement Next Steps Regarding the Compendium of Policies, Guidelines and Procedures in June 2016
/ PMPRB, What's New
In December 2015, the Patented Medicine Prices Review Board (PMPRB) posted a Notice and Comment seeking stakeholder comments on ... Read More
24
Mar2016
Ontario’s CED Will No Longer Routinely Evaluate CDR- or pCODR-Reviewed Drug Products
/ CDR, Ontario, pCODR, What's New
Effective April 1, 2016, all drug products reviewed by the Common Drug Review (CDR) and the pan-Canadian Oncology Drug Review ... Read More
15
Mar2016
The Ontario Public Drug Programs (OPDP) began funding INFLECTRA™ (infliximab) as a Limited Use (LU) benefit for eligible ODB recipients, ... Read More
15
Mar2016
The Canadian Agency for Drugs and Technologies in Health (CADTH) posted a call for patient input on March 11, ... Read More
10
Mar2016
The Canadian Agency for Drugs and Technologies in Health (CADTH) posted a call for patient input on March 9, ... Read More
10
Mar2016
The Ontario Ministry of Health and Long-Term Care (the ‘ministry’) is proposing to update recipient cost-sharing arrangements for non-low income ... Read More